



CAMERON M. KAPLAN, PH.D.  
*Gehr Family Center for Health Systems Science  
Keck School of Medicine  
University of Southern California*  
<http://keck.usc.edu/faculty/cameron-kaplan/>

2250 Alcazar St  
CSC 261  
Los Angeles, CA 90089

Office: (323) 442-0601  
Cell: (858) 245-3690  
Email: [kaplanc@usc.edu](mailto:kaplanc@usc.edu)

## EDUCATION

- 2011 Doctor of Philosophy in Economics, University of California, Santa Barbara  
2008 Master of Arts in Economics, University of California, Santa Barbara  
2005 Bachelor of Arts in Economics, Brandeis University

## UNIVERSITY APPOINTMENTS

- 2023– DIRECTOR  
2023– ASSOCIATE PROFESSOR (WITH TENURE)  
2018–2023 ASSISTANT PROFESSOR  
*Gehr Family Center for Health Systems Science  
University of Southern California*
- 2023– SENIOR FELLOW
- 2018–2023 FELLOW  
*Leonard D. Schaeffer Center for Health Policy & Economics  
University of Southern California*
- 2023– ASSOCIATE PROFESSOR  
2022–2023 ASSISTANT PROFESSOR  
Department of Population and Preventive Health Sciences  
*University of Southern California*
- 2013–2018 ASSISTANT PROFESSOR  
Department of Preventive Medicine  
*University of Tennessee Health Science Center*
- 2011–2013 POSTDOCTORAL ASSOCIATE  
Pharmaceutical Economics Research Group  
*University of Pittsburgh*

## CURRENT RESEARCH SUPPORT

*As Principal Investigator:*

- 2021–2025 “COVID-19 Mitigation Efforts and Disparities in Access to Routine Preventive Care and Chronic Disease Management” **CM Kaplan** PI. Funded by NIH-NIMHD (U01). \$1,842,990 (35% Effort)

- 2024-2025 “Outcomes of Alternative Payment Models” **CM Kaplan** & S Hempel Co-PI. Funded by AHRQ. \$520,000 (25% Effort)
- 2021-2025 “Examination of health disparity and its social determinants for vulnerable populations of COVID transmission” **CM Kaplan** PI. Funded by Social, Behavioral, & Economic COVID Coordinating Center. \$14,986 (5% Effort)

*As Co-Investigator or Sub-Contract PI:*

- 2023-2028 “Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations” Role: Sub-contract PI. S. Surbhi, PI (UTHSC). Funded by NIH-NIMHD (R01). \$3,700,000 (20% Effort)
- 2022-2027 “The Impact of Opioids on Health Outcomes for Hospitalized Infants” Role: Sub-contract PI. L. Kelly-Quon, PI (CHLA). Funded by NIH-NICHD. \$3,333,000 (15% Effort)
- 2021-2026 “Local Flavor Policies to Enhance Equity in Tobacco” Role: Sub-contract PI. S. Rose, PI (U. of KY). Funded by NIH-NCI (R01). \$2,830,000. (5% Effort)
- 2021-2026 “Quit4Life+: Adapting and Evaluating a Phone-Based Tobacco Use Cessation Program for People Living with HIV in Uganda and Zambia” Role: Co-I. H. Wipfli, PI. Funded by NIH-NCI (U01) . \$3,450,000. (5% Effort)
- 2024-2027 “Cardiovascular Health Learning Package” Funded by Los Angeles County Department of Public Health (5% Effort)
- 2024-2026 “Safety Net Innovation Award” Tsui J, PI. Funded by SC-CTSI (2% Effort)

**PAST RESEARCH SUPPORT**

*As Principal Investigator:*

- 2017-2021 “ACA Tobacco Surcharge: Affordability and Enrollment among Tobacco Users” **CM Kaplan**, PI. Funded by American Cancer Society. \$720,000
- 2017-2021 “Impact of Medicare Part D Gap Closure on Health Outcomes” **CM Kaplan** PI. Funded by NIH-NIA (R01). \$1,413,087
- 2019-2020 “Impact of Medicare Part D Gap Closure on Health Outcomes - Administrative Supplement” **CM Kaplan** PI. Funded by NIH-NIA (Supplement). \$75,059
- 2020-2021 “Examining Disparities in Testing for COVID-19 and Accessing Routine Care During a Pandemic ” **CM Kaplan/S Saluja** Co-PIs. Funded by WM Keck Foundation. \$35,000
- 2016-2017 “Corticosteroids Utilization and Initiation of Biologic Disease-Modifying Antirheumatic Drugs among Patients with Rheumatoid Arthritis” J Wang/C Spivey/**CM Kaplan** Co-PIs. Funded by Abbvie Pharmaceuticals. \$98,371
- 2016-2017 “Impact of Adalimumab Initiation on Co-Therapies and Associated Adverse Effects and Health Services Utilization among Patients with Rheumatoid Arthritis.” Wang/C Spivey/**CM Kaplan** Co-PIs. Funded by Abbvie Pharmaceuticals. \$99,876.
- 2016-2017 “Closing the Gap: Adherence and Medication Cost in Medicare Part D” **CM Kaplan** PI. Growing Research in Preventive Medicine Pilot Program. \$15,000

*As Co-Investigator:*

- 2019-2022 “Community Based Alzheimer’s Disease Initiative” Role: Sub-contract PI. E. Talamantes, PI (AltaMed). Funded by Administration of Community Living . \$992,500. (17% Effort)
- 2018-2021 “Impact of Medicare Value Programs on Inpatient Quality Indicators (IQIs) and Patient Safety Indicators (PSIs)” T Waters, PI. AHRQ (R01). \$1,398,379.
- 2017-2019 “The Role of Adverse Symptoms and Clinical Response on Racial Disparity Outcomes in Breast Cancer”, I Graetz, PI. Funded by NIH-NCI (R21). \$363,660
- 2015-2019 “Hospital Responses to Medicare Readmission Penalties” TM Waters PI. Funded by AHRQ (R01). \$749,998
- 2017-2018 “Online vs. in-person lay health advisor training for weight loss”, KH Yeary PI, I Graetz, UTHSC PI. UTHSC/UAMS CORNET Award in Cancer. \$50,000
- 2017-2018 “Relations between Long Acting Reversible Contraceptives and Sexually Transmitted Diseases” K Derefinko PI. Growing Research in Preventive Medicine Pilot Program. \$15,000
- 2015-2018 “Finding Equitable and Effective MTM Eligibility Criteria” J Wang PI. Funded by NIH-NIA (R01). \$1,316,752
- 2016-2018 “Strategies to promote cessation in smokers who are not ready to quit.” RC Klesges PI. Funded by NIH (R01). \$3,820,728.
- 2013-2015 “Community Oncology and Medical Home (COME HOME),” BA McAneny, PI, TM Waters, UTHSC PI. Funded by CMS Center for Medicare & Medicaid Innovation, \$19,757,338.

*As Consultant:*

- 2016-2019 “Phase 2 clinical trial for Veliparib in patients with Liver Cancer.” M Jones, PI. Funded by Abbvie Pharmaceuticals.

**PEER-REVIEWED PUBLICATIONS (In reverse chronological order)**

1. Rose SW, Thaxton Wiggins A, Patel M, Liu M, van de Venne J, Kucherlapaty P, Schillo B, Ickes M, Mattingly D, **Kaplan C**, Rayens MK. National longitudinal risk of tobacco use among youth and young adults in US local jurisdictions with and without flavor and comprehensive smoke-free policies, 2014-2019. *JNCI Monographs*. 2025 Aug;2025(70):243-52.
2. Keane OA, Ourshalimian S, **Kaplan C**, Gong C, Lakshmanan A, Hintz S, Lee HC, Ing M, Barq R, Nguyen N, Kelley-Quon LI. The Cost of Opioid Use in High-Risk Hospitalized Infants. *Journal of Surgical Research*. 2024 Oct 1;302:825-35.
3. **Kaplan CM**, Waters TM, Clear ER, Graves EE, Henderson S. The Impact of Prescription Drug Coverage on Disparities in Adherence and Medication Use: A Systematic Review. *Medical Care Research and Review*. 2024 Apr;81(2):87-95.
4. Keane OA, Ourshalimian S, Lakshmanan A, Lee HC, Hintz SR, Nguyen N, Ing MC, Gong CL, **Kaplan CM**, Kelley-Quon LI. Institutional and regional variation in opioid prescribing for hospitalized infants in the US. *JAMA Network Open*. 2024 Mar 4;7(3):e240555-.
5. Odegard MN, Ourshalimian SA, Chen SY, Russell CJ, Obinelo AU, **Kaplan CM**, Kelley-Quon LI. The impact of COVID-19 on racial and ethnic disparities in presentation with perforated appendicitis in children: A retrospective cohort study. *Surgery Open Science*. 2024 Mar 1;18:53-60.
6. Khalifeh, Z., Saluja, S., Lam, C. N., & **Kaplan, CM** (2024). Disparities in access to COVID-19 testing in Los Angeles County. *Preventive Medicine Reports*, 37, 102567.

7. Cohen-Cutler, S., **Kaplan, CM**, Olch, A., Wong, K., Malvar, J., Constine, L. S., & Freyer, D. R. (2023). Impact of Volumetric Dosimetry on the Projected Cost of Radiation-Related Late Effects Screening After Childhood Cancer: A Real-World Cohort Analysis. *The Oncologist*, oyad136.
8. Liu J, Zhang Y, **Kaplan CM**. Effects of Medicare Part D coverage gap closure on utilization of branded and generic drugs. *Health Economics*. 2023 Mar;32(3):639-53
9. Park KE, Saluja S, **Kaplan CM**. Alleviating Financial Hardships Associated with High-Deductible Health Plans for Adults with Chronic Conditions Through Health Savings Accounts. *Journal of General Internal Medicine*. 2023 Jan 4:1-6.
10. Hu X, **Kaplan CM**, Martin MY, Walker MS, Stepanski E, Schwartzberg LS, Vidal GA, Graetz I. Race Differences in Patient-Reported Symptoms during Chemotherapy among Women with Early-Stage Hormone Receptor–Positive Breast Cancer. *Cancer Epidemiology, Biomarkers & Prevention*. 2023 Feb 6;32(2):167-74.
11. Hu X, Walker MS, Stepanski E, **Kaplan CM**, Martin MY, Vidal GA, Schwartzberg LS, Graetz I. Racial Differences in Patient-Reported Symptoms and Adherence to Adjuvant Endocrine Therapy Among Women With Early-Stage, Hormone Receptor–Positive Breast Cancer. *JAMA Network Open*. 2022 Aug 1;5(8):e2225485-.
12. Waters TM, Burns N, **Kaplan CM**, Graetz I, Benitez J, Cardarelli R, Daniels MJ. Combined impact of Medicare’s hospital pay for performance programs on quality and safety outcomes is mixed. *BMC health services research*. 2022 Dec;22(1):1-8.
13. Kelley-Quon L, Zamora A, Ourshalimian S, Kim E, Leventhal A, **Kaplan CM**, Lakshmanan A (2022). “Iatrogenic Opioid Withdrawal in Hospitalized Infants.” *Journal of Perinatology*, 2022 Mar;42(3):399-400.
14. Lam CN, **Kaplan CM**, Saluja S. Relationship between mask wearing, testing, and vaccine willingness among Los Angeles County adults during the peak of the COVID-19 pandemic. *Translational Behavioral Medicine*. 2022 Mar;12(3):480-5.
15. Liu J, Zhang Y, **Kaplan CM**. (2022) “Differential Effects by Mental Health Status of Filling the Medicare Part D Coverage Gap”. *Medical Care*, 60(2):133-139.
16. Saluja S, Lam CN, Wishart D, McMorris A, Cousineau MR, **Kaplan CM** (2021). “Disparities in COVID-19 vaccine hesitancy among Los Angeles County adults after vaccine authorization.” *Preventive Medicine Reports*. 2021 Dec 1;24:101544
17. Potukuchi PK, Moradi H, Park F, **Kaplan CM**, Thomas F, Dashputre AA, Sumida K, Molnar MZ, Gaipov A, Gatwood JD, Rhee C. (2021) “Cannabis Use and Risk of Acute Kidney Injury in Patients with Advanced Chronic Kidney Disease Transitioning to Dialysis.” *Cannabis and Cannabinoid Research*. 2021 Oct 1.
18. Saluja S, **Kaplan CM**, Dhupati P, McCormick, D. (2021) “Preventing Financial Strain for Low-and Moderate-Income Adults: a Comparison of Medicaid, Marketplace, and Employer-Sponsored Insurance” *Journal of General Internal Medicine*, 2021, In Press.
19. Hu X, Chehal PK, **Kaplan CM**, Krukowski RA, Lan RH, Stepanski E, Vidal G, Graetz I. “Characterization of Clinical Symptoms by Race Among Women with Early-stage Hormone Receptor-Positive Breast Cancer Before Starting Chemotherapy.” *JAMA – Open*; 4(6):2021, e2112076.
20. **Kaplan CM** and Kaplan EK. State Policies Limiting Premium Surcharges for Tobacco and their Impact on Health Insurance Enrollment. *Health Services Research*. 2020 Dec 55(6):983-992.

21. Manz KC, Waters TM, **Kaplan CM**. Marketplace Premiums Rise Faster For Tobacco Users Because Of Subsidy Design: Study examines marketplace premiums paid by tobacco users. *Health Affairs*. 2020 Sep 1;39(9):1540-5
22. Yeary KH, **Kaplan CM**, Hutchins E. Implementation costs of a community health worker delivered weight loss intervention in black churches serving underserved communities. *Preventive Medicine Reports*. 2020 Apr 1:101084
23. Yeary KH, Ounpraseuth S, Wan F, Graetz I, Fagan P, Huff-Davis A, **Kaplan C**, Johnson K, Hutchins E. Assessing the Feasibility of an Online Training Designed to Enable Community Health Workers to Deliver a Comprehensive, Evidence-Based Weight Loss Intervention for Rural African Americans of Faith. *Journal of Cancer Education: the Official Journal of the American Association for Cancer Education*. 2020 May 21.
24. Derefinko KJ, Ashby S, Hayes T, **Kaplan C**, Bursac Z, García FI, Madjlesi A, Tonkin L, Bowden M, Popescu F, Waters T. Sexually Transmitted Infections and Contraceptive Use in Adolescents. *American Journal of Preventive Medicine*. 2020 Apr 1;58(4):536-46.
25. Spivey CA, Winthrop KL, Griffith J, **Kaplan CM**, Qiao Y, Postlethwaite AE, Wang J. Retrospective Analysis of the Impact of Adalimumab Initiation on Corticosteroid Utilization and Medical Costs Among Biologic-Naïve Patients with Rheumatoid Arthritis. *Rheumatology and Therapy*. 2020 Mar;7(1):133-47
26. **Kaplan CM**, Thompson M\*, Waters TM (2019). "How Have 30-Day Readmission Penalties Affected Racial/Ethnic Disparities in Readmissions?". *Journal of General Internal Medicine*, 2019 34(6):878-886.
27. Waters TM, **Kaplan CM**, Graetz I, Price M, Stevens L, McAneny B. "Patient-Centered Medical Homes in Community Oncology Practices: Changes in Spending and Care Quality Associated with the COME HOME Experience." *Journal of Oncology Practice*, 2019 Jan;15(1):e56-64.
28. McKillop CN\*, Graetz I, **Kaplan CM**, Kaplan EK, Thompson MP, Waters TM. "Three Years In – How Rising Premiums and Changes in Plan Availability in the US Health Insurance Marketplace May Affect the Frequency of Plan Switching." *BMC - Health Services Research*, 2018, 18:450.
29. Bursac Z, Klesges RC, Little MA, Linde BD, Popova L, **Kaplan CM**, Talcott GW. "The comparative effectiveness of two brief tobacco interventions in the U.S. Air Force: Perceived harm and intentions-to-use of tobacco products." *Tobacco Induced Diseases*. 2018;16(June):26
30. Graetz I, McKillop CN\*, **Kaplan CM**, and Waters, TM. "Lessons Learned from the Affordable Care Act: The Premium Subsidy Design May Promote Adverse Selection." *Medical Care Research and Review*, 2018 Dec;75(6):762-72.
31. Ali A\*, **Kaplan CM**, Derefinko KJ, Klesges, RC. "Smoking Cessation For Smokers Not Ready to Quit: Meta-Analysis and Cost-Effectiveness Analysis." *American Journal of Preventive Medicine*. 2018; Aug 1;55(2):253-62.
32. Spivey CA, Griffith J, **Kaplan CM**, Postlethwaite A, Ganguli A, Wang J. "A Retrospective Analysis of Corticosteroid Utilization Before Initiation of Biologic DMARDs Among Patients with Rheumatoid Arthritis in the United States." *Rheumatology and Therapy*, December, 2017:1-16.
33. Pesko MF, Maclean JC, **Kaplan CM**, and Hill SC. "Trends over time in enrollment in non-group health insurance plans by tobacco use in the United States". *Preventive Medicine Reports*, 2017; 7:46-49.
34. Thompson MP\*, **Kaplan CM**, Cao Y, Waters TM, Bazzoli GJ. "Most Hospitals Received Penalties for Excess Readmissions Every Year, But Some Fared Better Than Others." *Health Affairs*, 2017; 36(5):893-901.

35. Albert SM, Lunney JR, Ye L, Boudreau R, Ives D, Satterfield S, Waters T, **Kaplan CM**, Rubin S, Hilsa A, Newman A, Harris T. "Are Preferences for Aggressive Medical Treatment Associated with Health Care Utilization in the Very Old?" *Journal of Palliative Medicine*, 2017, 30(6):618-624.
36. Li T\*, Waters TM, Kaplan EK, **Kaplan CM**, Nyarko KA\*, Derefinko KJ, Talcot GW, Klesges RC. "Economic Analyses of an Alcohol Misconduct Prevention Program in a Military Setting." *Military Medicine*, 2017, 182(1) e1562 –e1567.
37. Thompson MP\*, **Kaplan CM**, Cao Y, Bazzoli GJ, Waters TM. "Reliability of 30-Day Readmission Measures Used in the Hospital Readmission Reduction Program." *Health Services Research*, 2016, 51(6): 2095-2114.
38. **Kaplan, C.M.** & Zhang, Y. "Anticipatory Behavior In Response To Medicare Part D's Coverage Gap." *Health Economics*, 2016, Published Online. DOI: 10.1002/hec.3311.
39. Liber A.C., Drope J.M., Graetz I., Waters T.M., **Kaplan C.M.** "Tobacco Surcharges on 2015 Health Insurance Plans Sold in Federally Facilitated Marketplaces: Variations by Age and Geography and Implications for Health Equity." *Am J Public Health*. 2015; 105( S5), S696-S698.
40. Waters TM, Webster JA, Stevens LA, Li T\*, **Kaplan CM**, Graetz, I, & McAneny, BL."Community Oncology Medical Homes: Physician-Driven Change to Improve Patient Care and Reduce Costs." *Journal of Oncology Practice*, 2015, 11(6), 462-467.
41. **Kaplan, C.M.** & Zhang, Y. "The January Effect: Medication Discontinuation among Medicare Part D Beneficiaries." *Health Economics*, 2014, 23(11):1287-1300.
42. Graetz, I., **Kaplan, C.M.**, Kaplan, E.K., Bailey, J.E., & Waters, T.M. "The U.S. Health Insurance Marketplace: Are Premiums Truly Affordable?", *Annals of Internal Medicine*, 2014, 161(8):599-604.
43. **Kaplan, C.M.**, Graetz, I., & Waters, T.M. "Most Exchange Plans Charge Lower Tobacco Surcharges Than Allowed, But Many Tobacco Users Lack Affordable Coverage." *Health Affairs*, 2014, 33(8).
44. Zhang, Y., **Kaplan, C.M.**, Baik, S., & Lave, J.R. "Medication Adherence and Readmission In Medicare Myocardial Infarction." *American Journal of Managed Care*, 2014, 20(11):e498-e505.
45. **Kaplan, C.M.** & Zhang, Y. "Assessing the Comparative-Effectiveness of Antidepressants Commonly Prescribed for Depression in the Medicare Population." *Journal of Mental Health Policy and Economics*, 2012, 15(4), 171–178.
46. Zhang, Y., Steinman, M.A., & **Kaplan C.M.** "Geographic Variations in Outpatient Antibiotic Prescribing in Older Adults." *Archives of Internal Medicine*, 2012, 172(19), 1–7.
47. Zhang, Y., Baik, S., Chang, C.H., **Kaplan C.M.**, & Lave, J.R. "Disability, Race/ethnicity, and Medication Adherence Among Medicare Myocardial Infarction Survivors." *American Heart Journal*, 2012, 164(3), 425-433.
48. Kaplan, R.M., Anderson, J.P. & **Kaplan C.M.** "Modeling Quality Adjusted Life Expectancy Loss Resulting From Tobacco Use in the United States." *Social Indicators Research*, 2007, 81(1), 51–64.

\* Indicates Post-Doctoral Trainee

#### NON-PEER REVIEWED PUBLICATIONS

*Published Commentary:*

1. **Kaplan CM.** "Capsule Commentary on Saloner et al., Price Transparency in Primary Care: Can Patients Learn About Costs When Scheduling an Appointment?." *Journal of General Internal Medicine*. 2017, Published Online.

2. **Kaplan, C.M.** "Capsule Commentary on Kesselheim et. al., Variations in Patients' Perceptions and Use of Generic Drugs: Results of a National Survey." *Journal of General Internal Medicine*, 2016, 31(6), 647.

*Opinion Articles:*

1. **Kaplan, CM** "The High Cost of 'Free' Covid Testing" Op-Ed in *Wall Street Journal*. February 3, 2022.

*Published Abstracts:*

1. **Kaplan CM**, Pastard W, Thacker J, Schneberk T, Lam CN, Axeen S, Tsui J. Abstract C129: Adapting to disruption?: Changes in colorectal cancer screening modalities and disparities during the COVID-19 pandemic. *Cancer Epidemiology, Biomarkers & Prevention*. 2024 Sep 21;33(9\_Supplement):C129-.
2. **Kaplan CM**, Pastard W, Lam CN, Solano L, Saluja S, Axeen S, Thacker J, Schneberk T, Tsui J. Abstract A140: Stool-Based Colorectal Cancer Screening During the COVID-19 Pandemic in a Safety-Net Setting: A Mixed-Methods Study. *Cancer Epidemiology, Biomarkers & Prevention*. 2024 Sep 21;33(9\_Supplement):A140-.
3. Hu X, Walker MS, Stepanski E, **Kaplan CM**, Martin MY, Vidal GA, Schwartzberg LS, Graetz I. "Race differences in patient-reported symptoms and adherence to adjuvant endocrine therapy among women with early-stage, hormone receptor-positive breast cancer." *Journal of Clinical Oncology*. 2022 40:S16
4. Shuvo S, Gatwood J, Tolley E, Surbhi S, **Kaplan C**, Bailey J. "Differences in Adherence and Health-care Utilization between Users of Analog Vial, Analog Pen, and Human Insulin." *Value in Health*. 2021 Jun 1;24:S13.
5. Cohen-Cutler S, **Kaplan C**, Olch A, Wong K, Malvar J, Constine LS, Freyer DR. Impact of using volumetric dosimetry to screen childhood cancer survivors for radiation-related late effects. *Journal of Clinical Oncology*. 39(15):S15
6. Hu X, **Kaplan C**, Stepanski E, Schwartzberg LS, Vidal GA, Walker MS, Martin MY, Graetz I. Differences by race in patient-reported symptoms during chemotherapy among women with early-stage, hormone receptor-positive breast cancer. *Journal of Clinical Oncology*. 39(15):S15.
7. Liu J, Zhang Y, **Kaplan CM**. How Do Medicare Beneficiaries Respond to Complex Cost-Sharing Design?. *9th Annual Conference of the American Society of Health Economists* 2020 Jun 9. ASHECON.
8. **Kaplan CM**, Hayes T. The Medicare Part D Coverage Gap Closure, Price Sensitivity, And Utilization: Which Drug Classes Saw The Largest Effect?. *Value in Health*. 2020 May 1;23:S295.
9. Yeary K, Ounpraseuth S, Wan F, Graetz I, Turner J, **Kaplan C**, Fagan P, Tate D. Online vs. in-person community health worker training modalities to deliver the Diabetes Prevention Program to produce weight loss in underserved African American communities. In *APHA's 2019 Annual Meeting and Expo* (Nov. 2-Nov. 6) 2019 Nov 4. APHA.
10. Ali A, **Kaplan C**. Changes in Prescription Drug Utilization Following Closure of the Medicare Part D Donut Hole. *2019 World Congress on Health Economics* 2019 Jul 15. iHEA.
11. Graetz I, Anderson JN, **Kaplan CM**. "The impact of the Medicare Part D donut hole closure on use and out-of-pocket costs for aromatase inhibitors". *Cancer Research*, 2018, 78, Suppl. 13:4765.
12. Qiao Y, Winthrop KL, Griffith J, **Kaplan CM**, Spivey CA, Postlethwaite A, Wang J. "Effects of adalimumab initiation on corticosteroid utilisation and medical costs among patients with rheumatoid arthritis." *Annals of the Rheumatic Diseases*, 2018, 77, Suppl. 2:523.

13. Spivey CA, Griffith J, **Kaplan CM**, Postlethwaite A, Ganguli A, Wang J. "Impact of corticosteroid utilization on biologic disease-modifying antirheumatic drug initiation among patients with rheumatoid arthritis." *Annals of the Rheumatic Diseases*, 2017, 76, Suppl. 2:1504.
14. Thompson MP\*, **Kaplan CM**, Bazzoli GJ, and Waters TM. "Comparing Changes in Hospital Readmission Rates by Frequency and Total Financial Penalties Over the First Five Years". *Circulation: Cardiovascular Quality and Outcomes*, 2017, 10:A027.
15. Vanderwalde NA, Li T\*, **Kaplan CM**, Kaplan EK, Stevens L, Webster J, McAneny BL, & Waters TM "Uncontrolled chronic conditions prior to cancer diagnosis in older adults as a predictor of unplanned hospitalizations during cancer care: A Medicare claims analysis." *ASCO Annual Meeting Proceedings*, 2015, 33(15), 6587.
16. Kaplan RM, Morton D, Anderson, JP, Jo H, & **Kaplan CM**. "Modeling Quality-Adjusted Life Expectancy Loss Resulting From Tobacco Use in California." *California Tobacco Related Disease Research Program*, 2003.

*Theses:*

1. **Kaplan CM**. *Three Essays on the Economics of Health Behavior and Outcomes*, Doctoral Dissertation, UMI Dissertation Publishing, 2011.
2. **Kaplan CM**. "Worker Productivity: How Job Status Can Moderate the Economic Impact of Illness," Undergraduate Honors Thesis, *Brandeis University Archives* (no. 1197), 2005.

**INVITED LECTURES/PRESENTATIONS**

*Invited Seminars:*

2019	Gehr Center for Health Systems Science, Health Policy Debate
2019	American Cancer Society, Economic and Health Policy Research Division
2018	University of Southern California, Department of Preventive Medicine
2017	University of Southern California, Leonard D. Schaeffer Center for Health Policy and Health Economics & Gehr Family Center for Health Systems Science
2016	Bluff City Medical Society
2016	San Diego State University, Graduate School of Public Health
2013	Health Systems Research Conference, University of Tennessee Health Science Center
2013	University of Tennessee Health Science Center, Dept. of Preventive Medicine
2013	University of West Virginia, Dept. of Health Policy, Management and Leadership
2013	University of British Columbia, Faculty of Pharmaceutical Sciences
2013	University of California - Merced, School of Social Sciences, Humanities and Arts
2013	Research Triangle Institute
2012	University of Tennessee Health Science Center, Dept. of Preventive Medicine
2011	University of Maryland, Dept. of Pharmaceutical Health Services Research

*Conference Oral Presentations (as speaker):*

- 2022 **Kaplan CM** & Hayes T “Which Drugs Were Most Responsive to the Medicare Part D Donut Hole Closure?” *ASHEcon* 2022. June, 2022, Austin, TX
- 2022 **Kaplan CM**, Lam CN, Tsui, J, Saluja S, Schneberk T, Axeen S. “Disparities in Outpatient Care and Televisits Use during the COVID-19 Pandemic among Patients with Hypertension or Diabetes” *NIH Social, Behavioral and Economic Outcomes in COVID-19 Conference*. April 27, 2022, Online
- 2020 **Kaplan CM** & Kaplan EK. “Tobacco Premium Surcharges in the Health Insurance Marketplaces: The Impact of State Policy” UCSB Alumni Conference. August 6, 2020, Online/Santa Barbara, CA
- 2020 **Kaplan CM** & Kaplan EK. “Tobacco Premium Surcharges in the Health Insurance Marketplaces: The Impact of State Policy” Academy Health Annual Research Meeting. June 13, 2020, Online/Boston, MA
- 2020 **Kaplan CM** & Kaplan EK. “Tobacco Premium Surcharges in the Health Insurance Marketplaces: The Impact of State Policy” American Society of Health Economists Annual Conference. June 9, 2020, Online/St. Louis, MO.
- 2020 Liu J, Zhang Y & **Kaplan CM**. How Do Medicare Beneficiaries Respond to Complex Cost-Sharing Design? American Society of Health Economists Annual Conference. June 9, 2020, Online/St. Louis, MO.
- 2020 **Kaplan CM** & Hayes T. “Price Sensitivity and Substitution among Prescription Medications: Evidence from the Medicare Part D Donut Hole Closure” 13th Annual International Conference on Health Policy Statistics. January 7, 2020, San Diego, CA
- 2017 **Kaplan CM**, Thompson MP, and Waters TM. “How Have 30-Day Readmission Penalties Affected Racial/Ethnic Disparities in Readmissions?.” *Academy Health Annual Research Meeting*. June 26, 2017, New Orleans, LA.
- 2016 **Kaplan CM**, Liber AC, & Graetz I. “ACA Tobacco Penalties Lead to Lying and Under-Enrollment Among Smokers.” *Academy Health Annual Research Meeting*. June 26, 2016, Boston, MA.
- 2016 Kaplan EK, **Kaplan CM**, Graetz I & Waters TW. “Labor Supply Impacts of the Affordable Care Act.” *Tennessee Empirical Applied Microeconomics Festival*. May 17, 2016, Knoxville, TN.
- 2015 **Kaplan CM**, Kaplan EK, Nyarko K, Graetz I & Waters TW. “How Do ACA Premiums Change in 2015?: The Impact of Market Entry and Exit.” *Academy Health Annual Research Meeting*. June 14, 2015, Minneapolis, MN.
- 2014 **Kaplan CM**. “Should Out-of-Pocket Cost for Medications Depend on Clinical Status?: Evidence from the Medical Expenditure Panel Survey” *International Health Economics Association/European Conference on Health Economics Congress*. July 13, 2014. Dublin, Ireland.
- 2014 Kaplan EK, **Kaplan CM**, Graetz IP & Waters TW. “Early Impact of Affordable Care Act Subsidies on Labor Market Supply.” *Academy Health Annual Research Meeting*. June 10, 2014, San Diego, CA.
- 2013 **Kaplan CM** & Zhang Y. “Anticipatory Effects of Nonlinear Design Features of the Medicare Prescription Drug Benefit.” *Academy Health Annual Research Meeting*. June 25, 2013, Baltimore, MD.
- 2013 **Kaplan CM** & Zhang Y. “Anticipatory Effects of Nonlinear Design Features of the Medicare Prescription Drug Benefit.” *Allied Social Science Associations Annual Meeting - American Economic Association*. January 6, 2013, San Diego, CA.

- 2013 **Kaplan CM.** “Risk Compensation and Treatment for High Cholesterol.” *Allied Social Science Associations Annual Meeting - Health Economics Research Organization*. January 5, 2013, San Diego, CA.
- 2012 **Kaplan CM.** & Zhang Y. “The January Effect: Medication Discontinuation and Reinitiation among Medicare Part D Beneficiaries.” *American Society of Health Economists Biennial Conference*. June 11, 2012, Minneapolis, MN.
- 2012 Zhang Y, Baik S, Chang CH, **Kaplan CM** & Lave JR. “Variations in Medication Adherence among Medicare Myocardial Infarction Survivors,” *American Society of Health Economists Biennial Conference*. June 11, 2012, Minneapolis, MN.
- 2012 **Kaplan CM** & Zhang Y. “Assessing the Comparative Effectiveness of Antidepressants Commonly Prescribed for Depression in the Medicare Population.” *American Society of Health Economists Biennial Conference*. June 13, 2012, Minneapolis, MN.
- 2011 **Kaplan CM.** “Risk Compensation and Treatment for High Cholesterol.” *International Health Economics Association World Congress*. July 12, 2011, Toronto, ON.

*Conference Poster Presentations:*

- 2022 **Kaplan CM,** Saluja S, Graez I. “Knowledge of Tobacco Premium Surcharges Among Tobacco Users Eligible for Affordable Care Act Marketplace Plans and Impact on Tobacco Cessation.” *Academy Health Annual Research Meeting*. June, 2022, Washington, DC
- 2022 **Kaplan CM,** Lam CN, Tsui, J, Saluja S, Schneberk T, Axeen S. “Disparities in Outpatient Care and Televisits Use during the COVID-19 Pandemic among Patients with Hypertension or Diabetes” *Academy Health Annual Research Meeting*. June, 2022, Washington, DC
- 2022 **Kaplan CM** & Hayes T “Which Drugs Were Most Responsive to the Medicare Part D Donut Hole Closure?” *Academy Health Annual Research Meeting*. June, 2022, Washington, DC
- 2020 **Kaplan CM** & Hayes T “The Medicare Part D Coverage Gap Closure, Price Sensitivity, and Utilization: Which Drug Classes Saw The Largest Effect?” *Academy Health Annual Research Meeting*. June 15, 2020, Boston, MA (Cancelled due to COVID-19)
- 2020 Manz K, Waters TM, & **Kaplan CM.** “Due to Subsidy Design, Marketplace Premiums Rise Faster for Tobacco Users” *Academy Health Annual Research Meeting*. June 13, 2020, Boston, MA (Cancelled due to COVID-19)
- 2020 Saluja S, Graetz I & **Kaplan CM.** “Awareness and Understanding of Tobacco Surcharges in Affordable Care Act Marketplace Plans and the Impact of Surcharges on Insurance Enrollment and Tobacco Reporting” *Academy Health Annual Research Meeting*. June 13, 2020, Boston, MA. (Cancelled due to COVID-19)
- 2020 **Kaplan CM** & Hayes T “The Medicare Part D Coverage Gap Closure, Price Sensitivity, and Utilization: Which Drug Classes Saw The Largest Effect?” *ISPOR*. May 19, 2020, Orlando, FL (Cancelled due to COVID-19)
- 2020 **Kaplan CM** & Hayes T “Price Sensitivity and Substitution among Prescription Medications: Evidence from the Medicare Part D Donut Hole Closure” *Allied Social Science Associations Annual Meeting - American Economic Association*. January 3, 2020, San Diego, CA
- 2014 **Kaplan CM,** Graetz IP, & Waters TW. “Variation in the Tobacco Surcharge and Plan Affordability for Tobacco-Users under the Affordable Care Act” *Academy Health Annual Research Meeting*. June 10, 2014, San Diego, CA.

- 2013      **Kaplan CM** & Zhang Y. “Geographic Variation in Utilization of Mental Health Drugs among Medicare Beneficiaries.” *Academy Health Annual Research Meeting*. June 25, 2013, Baltimore, MD.
- 2013      Zhang Y, **Kaplan CM**, Baik S, Chang CH & Lave JR. “Medication Adherence and Readmission in Medicare Myocardial Infarction” *Academy Health Annual Research Meeting*. June 25, 2013, Baltimore, MD.
- 2012      **Kaplan CM** & Zhang Y. “Assessing the Comparative Effectiveness of Antidepressants Commonly Prescribed for Depression in the Medicare Population.” *Academy Health Annual Research Meeting*. June 24, 2012, Orlando, FL.
- 2006      **Kaplan CM**, Shepard DS, and Neighbors CJ. “Worker Productivity: How Job Status Can Moderate the Economic Impact of Illness.” *Academy Health Annual Research Meeting*. June 25, 2006, Seattle, WA.

## TEACHING EXPERIENCE

### *As Instructor of Record:*

- “Public Health Policy and Politics,” USC, Spring 2022, Spring 2023, Spring 2024, Spring 2025. Three credit hours, 23-26 students.
- “Public Health Policy and Politics (Co-Instructor with M. Cousineau),” USC, Spring 2020. Three credit hours, 24 students.
- “Biostatistics for Public Health,” UTHSC, Fall 2016. Three credit hours, 8 students.
- “Economics of Health and Healthcare,” UTHSC, Fall 2015. Three credit hours, 2 students.
- “Applied Econometrics with Lab,” California State University - Channel Islands, Fall 2008, Spring 2009, Fall 2010. Four credit hours, enrollments ranged from 12-25 students.
- “Principles of Microeconomics,” University of California - Santa Barbara, Summer Quarter 2008. Three credit hours, 97 students.

### *As Guest Lecturer:*

- “M1 and M2 Health Policy Lecture Series,” USC, Lectures on ACA, Pharmaceutical Policy, Private Health Insurance, etc. 2018-2025
- “Gehr Summer Program,” USC, Lectures on hospital financing and data/research methods. 2019-2025
- “Health Policy Intersession (M2),” USC, Lectures on ACA, COVID-19, and Pharmaceutical Policy, 2019-2024
- “Health Services Delivery,” USC, Lectures on International Comparison of Health Systems, 2019-2025
- “Health Services Research Methods,” USC, Lectures on Cost-Effectiveness Analysis, 2019-2025
- “M4 Capstone” University of Tennessee Health Science Center, Lecture on ACA in Tennessee, Spring 2014.
- “M4 Capstone” University of Tennessee Health Science Center, Lectures on Costs in US Healthcare system and the ACA. Summer 2014, Fall 2014, Spring 2015, Spring 2018.

- “Advanced Empirical Microeconomics Methods with Applications for Healthcare Research,” University of Pittsburgh, Two weeks each in Spring 2012 & Spring 2013, 3-4 students.

*As Teaching Assistant:*

- “Principles of Microeconomics,” University of California - Santa Barbara, Fall 2005, Winter 2006, Spring 2006, Fall 2006, Fall 2007, Winter 2008, Spring 2008, Winter 2009, Spring 2009, Fall 2010.
- “Principles of Macroeconomics,” University of California - Santa Barbara, Winter 2007.
- “Intermediate Microeconomics,” University of California - Santa Barbara, Spring 2007, Fall 2008.
- “Statistics With Economics And Business Applications,” University of California - Santa Barbara, Winter 2011.
- “Health Economics,” University of California - Santa Barbara, Winter 2009.
- “Economics of Insurance,” University of California - Santa Barbara, Winter 2009.

*PhD Dissertation Committees:*

- Kiraat Munshi
- Praveen Potukuchi
- Sohul Shuvo

*Summer Medical Student Research Mentees:*

- Neal Nathan
- Sam Melville
- Kristen Park
- Nathan Menard
- Danielle Wishart
- Zain Khalifeh
- Teresa Rokos
- Mingdong Lyu
- Rebecca Braganca
- Meghna Srivastava
- Faeben Wossenseged
- Ruth Hailu
- Edward Chauca
- Gabrielle Smith

*Post-Doctoral Trainees:*

- Kwame Nyarko
- Tao Li
- Caitlin McKillop
- Mike Thompson
- Shane Murphy
- Ayesha Ali
- Guadalupe Ramos

## HONORS AND AWARDS

- 2005 Undergraduate Thesis Completed with High Honors, Brandeis University
- 2009 Economics Teaching Assistant of the Year, University of California, Santa Barbara
- 2017 HCUP 2016 Outstanding Article of the Year Award, Policy Winner

## EDITORIAL SERVICE

Grant Review Study Sections: *American Cancer Society CPHPS/HOPS Peer Review Committee Member (2020-2023)*

Ad-Hoc Grant Review: *Robert Wood Johnson Foundation, NIH (Health Services Organization and Delivery Study Section, NIH Member Conflict Health Services & Informatics, NIH Health Services Research on Minority Health and Health Disparities Special Emphasis Panel), Keck Foundation, Institute for Addiction Science*

Editorial Boards: *PLOS One (Academic Editor)*

Ad-Hoc Manuscript Reviewer: *Health Economics; Health Services Research; Health Affairs; Medical Care; American Journal of Managed Care; Economics of Education Review; Pharmacoepidemiology and Drug Safety (Top Reviewer in 2012), Journal of General Internal Medicine, Psychiatric Services, International Journal of Environmental Research and Public Health, PLOS One, Inquiry, Journal of Health and Human Services Administration, American Journal of Public Health, Journal of Statistical Computation and Simulation, Clinical Journal of the American Society of Nephrology*

Scientific Committee: *IHEA and ECHE Joint Congress 2014, IHEA World Congress 2015*

Discussant: *Allied Social Science Associations Annual Meeting (2013, San Diego); American Society of Health Economists Biennial Conference (2014, Los Angeles); IHEA and ECHE Joint Congress 2014 (Dublin, 2014), American Society of Health Economists (2022, Austin)*

Conference Session Chair: *IHEA and ECHE Joint Congress 2014 (Dublin, 2014), American Society of Health Economists (2022, Austin)*

## SOCIETY MEMBERSHIPS

- American Economic Association
- International Health Economics Association
- American Society of Health Economists
- Health Economics Research Organization
- AcademyHealth
- Southern Economic Association